In summary, glycoprotein vaccine manufacturing C1 production platform appears entirely suitable for rapid commercial development of SARS-CoV-2 vaccine, which would be relatively unaffected by lack of resources, such as shortages of materials (e.g., plastic bags for insect cell vaccine manufacturing), equipment, expensive media, and cold-chain freezers. Based on the data of this study and further development under GMP conditions for the first time, a subunit antigen vaccine produced in C1-cells received regulatory approval to initiate a Phase 1 clinical trial to demonstrate safety and efficacy in humans [55].
The above quote is taken from the published paper.
I think when people give up on a stock is the time to start buying. HC Wainwright & Co. Reiterates Buy on Dyadic International, Maintains $6 Price Target i do not believe the $6 price target but I feel the risk reward is favorable and the story is good.